As of June 30, 2024, Henlius (02696.HK) announced that the group's total revenue for the six months was approximately RMB 27.461 billion, mainly from pharmaceutical sales, research and development services provided to customers, and licensing revenue, an increase of approximately RMB 24.56 billion compared to the six months ending June 30, 2023, an increase of about 9.8%.

For the six months ending June 30, 2024, the group's profit was approximately RMB 38.63 billion, an increase of approximately RMB 14.63 billion compared to the profit of approximately RMB 24.00 billion for the six months ending June 30, 2023, mainly due to the continuous commercialization and expanding sales volume of core products.

As of August 23, 2024, the group has successfully launched 5 products (23 indications) for sale in China, with 3 products approved for listing in Europe, the USA, Canada, Australia, Indonesia, and other countries/regions. Hanquyi was approved by the US Food and Drug Administration (FDA) for the treatment of breast cancer, metastatic breast cancer, and metastatic gastric cancer. Furthermore, the New Drug Submission (NDS) for Hanquyi was approved by Health Canada. Hansizhuo expanded its commercial footprint successfully in Cambodia and Thailand, and Hanlicon was approved for listing in Peru, highlighting the group's growing international presence.

As of the most recent feasible date, the group's pipeline includes over 50 molecules and 14 research platforms, covering various forms of pharmaceuticals such as monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, recombinant proteins, and small molecule conjugates.

The group places importance on preclinical project reserves and successfully obtained approval for clinical trial applications (IND) for the GARP/TGF-β1, TIGIT+PD-1+VEGF target projects during the reporting period, entering clinical research smoothly.

The group has a total commercialization capacity of 48,000 liters (including 24,000 liters of commercialization capacity at Xuhui Base and 24,000 liters of commercialization capacity at Songjiang Base (Phase I)). During the reporting period, Xuhui Base successfully completed multiple overseas customer audits for products such as Hansizhuo, Hanquyi, and Handayuan; Songjiang Base (Phase I) has passed the Pre-License Inspection (PLI) by the US Food and Drug Administration (FDA) for the injection of trastuzumab biosimilar HERCESSITM (Chinese brand name: Hanquyi, European brand name: Zercepac), indicating that the relevant production sites and facilities have obtained FDA certification; Phase III of Songjiang Base (Phase II) has completed the main structure topping out during the reporting period.

In the second half of the year, the group will continue to focus on clinical needs, deepen its presence in areas such as oncology and autoimmune diseases, enhance product innovation, market expansion, and international cooperation, solidify its integrated capabilities in research, production, and sales, and steadily develop in the Biopharma sector with greater scale, internationalization, and sustainable profitability.